- Home
- BCV vs SGMO Comparison
BCV vs SGMO Comparison
Compare BCV & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCV
- SGMO
- Stock Information
- Founded
- BCV 1971
- SGMO 1995
- Country
- BCV United States
- SGMO United States
- Employees
- BCV N/A
- SGMO N/A
- Industry
- BCV Finance/Investors Services
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCV Finance
- SGMO Health Care
- Exchange
- BCV Nasdaq
- SGMO Nasdaq
- Market Cap
- BCV 104.8M
- SGMO 122.8M
- IPO Year
- BCV N/A
- SGMO 2000
- Fundamental
- Price
- BCV $18.26
- SGMO $0.46
- Analyst Decision
- BCV
- SGMO Buy
- Analyst Count
- BCV 0
- SGMO 6
- Target Price
- BCV N/A
- SGMO $4.50
- AVG Volume (30 Days)
- BCV 26.3K
- SGMO 4.1M
- Earning Date
- BCV 01-01-0001
- SGMO 08-05-2025
- Dividend Yield
- BCV 8.13%
- SGMO N/A
- EPS Growth
- BCV N/A
- SGMO N/A
- EPS
- BCV N/A
- SGMO N/A
- Revenue
- BCV N/A
- SGMO $63,756,000.00
- Revenue This Year
- BCV N/A
- SGMO N/A
- Revenue Next Year
- BCV N/A
- SGMO N/A
- P/E Ratio
- BCV N/A
- SGMO N/A
- Revenue Growth
- BCV N/A
- SGMO 239.92
- 52 Week Low
- BCV $14.09
- SGMO $0.30
- 52 Week High
- BCV $18.11
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- BCV 50.83
- SGMO 38.27
- Support Level
- BCV $18.17
- SGMO $0.49
- Resistance Level
- BCV $18.49
- SGMO $0.51
- Average True Range (ATR)
- BCV 0.17
- SGMO 0.04
- MACD
- BCV -0.06
- SGMO 0.01
- Stochastic Oscillator
- BCV 32.67
- SGMO 6.25
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.